2016
HOXB13 and other high penetrant genes for prostate cancer
Pilie P, Giri V, Cooney K. HOXB13 and other high penetrant genes for prostate cancer. Asian Journal Of Andrology 2016, 18: 530-532. PMID: 27034017, PMCID: PMC4955175, DOI: 10.4103/1008-682x.175785.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsGenetic Predisposition to DiseaseGenotypeHomeodomain ProteinsHumansMaleProstatic NeoplasmsConceptsHereditary cancer syndromesMismatch repair genesCancer syndromesGermline mutationsProstate cancerMultiple primary malignanciesOvarian cancer syndromeCancer family syndromeDeleterious germline mutationsRare tumor typeCancer cell growthRepair genesHigh-penetrance genesPenetrant germline mutationsPrimary malignancyCommon cancerLi-FraumeniKey tumor suppressor genesFamily syndromeCancer tissuesHereditary breastTumor typesSyndromeCancer typesCancer
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2012
Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection
Hughes L, Zhu F, Ross E, Gross L, Uzzo R, Chen D, Viterbo R, Rebbeck T, Giri V. Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 53-60. PMID: 22144497, PMCID: PMC3253936, DOI: 10.1158/1055-9965.epi-11-0727.Peer-Reviewed Original ResearchConceptsEarly-onset prostate cancerProstate cancer early detectionHigh-risk menCancer early detectionAfrican American menProstate cancerEarly detectionAmerican menConcordance indexClinical informationProstate cancer risk assessmentCancer diagnosisHarrell's concordance indexAfrican American raceFamilial prostate cancerUseful clinical informationCancer risk assessmentStudy criteriaLongitudinal cohortFamily historyAge 35Clinical roleCox modelEligibility criteriaAmerican race
2011
Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent
Chang B, Spangler E, Gallagher S, Haiman C, Henderson B, Isaacs W, Benford M, Kidd L, Cooney K, Strom S, Ingles S, Stern M, Corral R, Joshi A, Xu J, Giri V, Rybicki B, Neslund-Dudas C, Kibel A, Thompson I, Leach R, Ostrander E, Stanford J, Witte J, Casey G, Eeles R, Hsing A, Chanock S, Hu J, John E, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck T. Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 23-32. PMID: 21071540, PMCID: PMC3110616, DOI: 10.1158/1055-9965.epi-10-0698.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesProstate cancer susceptibility regionsGenome-wide significanceGWAS-identified lociCancer susceptibility lociGenetic etiologyProstate cancer susceptibility allelesEuropean descentGenetic variationCancer susceptibility allelesEuropean-descent populationsAssociation studiesSusceptibility lociGenotype dataLociSusceptibility regionsChromosome 8q24Susceptibility allelesDescent populationsRegion 2Prostate cancer associationRs12418451MSMBRs10993994Alleles